GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » 1-Year ROIIC %

IntelliPharmaCeutics International (IntelliPharmaCeutics International) 1-Year ROIIC % : 84.37% (As of Aug. 2023)


View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. IntelliPharmaCeutics International's 1-Year ROIIC % for the quarter that ended in Aug. 2023 was 84.37%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for IntelliPharmaCeutics International's 1-Year ROIIC % or its related term are showing as below:

IPCIF's 1-Year ROIIC % is ranked better than
73.19% of 1462 companies
in the Biotechnology industry
Industry Median: -2.96 vs IPCIF: 84.37

IntelliPharmaCeutics International 1-Year ROIIC % Historical Data

The historical data trend for IntelliPharmaCeutics International's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International 1-Year ROIIC % Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
1-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,232.89 -787.79 -1,522.99 -63.81 208.71

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -76.67 208.71 794.70 2,077.61 84.37

Competitive Comparison of IntelliPharmaCeutics International's 1-Year ROIIC %

For the Biotechnology subindustry, IntelliPharmaCeutics International's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's 1-Year ROIIC % falls into.



IntelliPharmaCeutics International 1-Year ROIIC % Calculation

IntelliPharmaCeutics International's 1-Year ROIIC % for the quarter that ended in Aug. 2023 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -2.53 (Aug. 2023) - -3.788 (Aug. 2022) )/( 4.01 (Aug. 2023) - 2.887 (Aug. 2022) )
=1.258/1.123
=112.02%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


IntelliPharmaCeutics International  (OTCPK:IPCIF) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


IntelliPharmaCeutics International 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Headlines

From GuruFocus

Intellipharmaceutics Reports Director Election Results

By ACCESSWIRE ACCESSWIRE 02-05-2022

Intellipharmaceutics Comments on Recent Trading Activity

By ACCESSWIRE ACCESSWIRE 12-22-2021